University of California, Los Angeles
Pathology residency · Los Angeles, CA · Program website
- 4
- Faculty
- 24
- Trainees
- 139
- Papers
- 33%
- Trainees published
- 34%
- First author
7 people are awaiting a match decision, so numbers may change.
Papers
By this program's faculty and trainees since 2022, 139 in all. Updated 2026-11-07.
- A Roadmap for Developing and Implementing Duffy Null-Specific Reference IntervalsLauren E. Merz et al. · Blood Advances · 2026 · PubMed
- Establishing Absolute Neutrophil Count and White Blood Cell Count Reference Intervals for the Duffy Null PopulationLauren E. Merz et al. · Blood Advances · 2026 · PubMed
- Mobile point-of-care testing to improve access to care for people experiencing homelessness and diabetes in Los AngelesTobin Berger-Cahn et al. · American Journal of Clinical Pathology · 2026 · PubMed
- 3025 – TARGETING IGF2BP1 DISRUPTS THE PI3K PATHWAY AND ACTIVATES METABOLIC REPROGRAMMING IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAIshu Bansal et al. · Experimental Hematology · 2026
- Neuroimmune phenotypes in brain aneurysms and neurodegenerative diseasesFrancis Joseph Lauzier et al. · Frontiers in Neuroscience · 2026 · PubMed
- Hepatocellular Carcinoma With a Grade 3 Neuroendocrine Tumor Component: A Case ReportXue Wen et al. · International Journal of Surgical Pathology · 2026 · PubMed
- Neuropathology of centenarians and supercentenarians: An autopsy studyShino Magaki et al. · Neurobiology of Aging · 2026 · PubMed
- POSTER: ALL-1707: IGF2BP1 Inhibition Impairs PI3K Signaling and Drives Metabolic Reprogramming in B-Cell Acute Lymphoblastic LeukemiaIshu Bansal et al. · Clinical Lymphoma Myeloma & Leukemia · 2026
- IGF2BP3 remodels RISC occupancy to control microRNA targeting in leukemiaLyna E.S. Kabbani et al. · NAR Cancer · 2026 · PubMed · cited 1
- Targeting RNA-Binding Oncofetal Protein IGF2BP3: Discovery of Potent and Selective InhibitorsGeorgia Scherer et al. · Journal of Medicinal Chemistry · 2026 · PubMed
How trainees publishauthor positions, faculty co-authorship, ranks
Papers by current residents and fellows, and alumni within two years, published during training. Based on 8 of 24 trainees matched to publication records. Trainees with no match count as not yet published, so these figures are a floor.
Faculty detailsh-index, papers and author positions per person
Program leadership from the program's own pages, matched to publications. Leadership is mostly clinician-educators, so these numbers describe the teaching team, not the department's research. Works since 2022-01-01.
| Name | Research topics | h (lifetime) | Works | 1st | Last | Median FWCI |
|---|---|---|---|---|---|---|
| Dinesh S. Rao, MD, PhD | Acute Myeloid Leukemia Research; Acute Lymphoblastic Leukemia research | 43 | 24 | 0 | 8 | 1.74 |
| Zhen W. Mei, MD | Blood transfusion and management; Blood groups and transfusion | 5 | 10 | 1 | 0 | 0.19 |
| Chana R. Sachs, MD | Renal cell carcinoma treatment; Endometrial and Cervical Cancer Treatments | 2 | 4 | 0 | 0 | 1.65 |
| Diana R. Vulcain, MD | Breast Lesions and Carcinomas; Clinical Laboratory Practices and Quality Control | 0 | 3 | 0 | 0 | — |
24 trainees are counted above but never listed by name.
About University of California, Los Angelesinstitution-wide pathology research
Pathology publications from University of California, Los Angeles and affiliated institutions, since 2022. Updated 2026-11-06; refreshed daily.
Works per year · * 2026 so far
Pathology research topics at University of California, Los Angeles
Papers in the window; each links to the list on OpenAlex.
Most cited at University of California, Los Angeles since 2024
All pathology papers there on OpenAlex
- Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric, Version 3.2024, NCCN Clinical Practice Guidelines In OncologyRachel Hodan et al. · Journal of the National Comprehensive Cancer Network · 2024 · PubMed · cited 126
- Glucagon-Like Peptide-1 Receptor Agonist Medications Alter Outcomes of Spine SurgeryJoshua M. Wiener et al. · Spine · 2025 · PubMed · cited 43
- Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysisSimon Arnett et al. · Journal of Neurology · 2024 · PubMed · cited 39
- Glucarpidase for treatment of high-dose methotrexate toxicityShruti Gupta et al. · Blood · 2025 · PubMed · cited 37
- 4D marmoset brain map reveals MRI and molecular signatures for onset of multiple sclerosis–like lesionsJing‐Ping Lin et al. · Science · 2025 · PubMed · cited 36
- Antigen specificity of clonally enriched CD8+ T cells in multiple sclerosisFumie Hayashi et al. · Nature Immunology · 2026 · PubMed · cited 31
- A scoping review of the epidemiology of systemic sclerosis and its organ manifestations: 2018–2024Samuel D. Good et al. · Current Opinion in Rheumatology · 2024 · PubMed · cited 29
- NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025Andrew David Zelenetz et al. · Journal of the National Comprehensive Cancer Network · 2025 · PubMed · cited 28
- Microsatellite instability in mismatch repair proficient colorectal cancer: clinical features and underlying molecular mechanismsYun Xu et al. · EBioMedicine · 2024 · PubMed · cited 27
- Insights into DNA repeat expansions among 900,000 biobank participantsMargaux L.A. Hujoel et al. · Nature · 2026 · PubMed · cited 26